一个gB纳米粒子疫苗引起了对EBV的保护性中和抗体反应
Cong Sun1, Yin-Feng Kang1, Xin-Yan Fang2
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China.
Cell host & microbe
|October 17, 2023
概括
一种新的爱斯坦-巴尔病毒 (EBV) 纳米粒子疫苗候选者,gB-I53-50 NP,在临床前模型中显示出增强的免疫性,并保护免受致命的EBV挑战,为新的EBV疫苗提供了一个有前途的平台.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗开发 疫苗开发
背景情况:
- 爱斯坦-巴尔病毒 (EBV) 是一个重要的全球健康问题,与许多疾病和癌症有关.
- 目前没有针对EBV的预防性疫苗存在,这突显了严重的未满足的医疗需求.
- EBV 糖蛋白 B (gB) 对于病毒进入宿主细胞至关重要,使其成为疫苗策略的关键目标.
研究的目的:
- 开发和评估一种基于纳米粒子的新型疫苗,针对EBV糖蛋白B (gB).
- 在临床前模型中评估gB纳米颗粒疫苗的免疫性和保护功效.
主要方法:
- 一个gB纳米粒子 (gB-I53-50 NP) 显示多个副本的gB被工程.
- 对gB-I53-50 NP的结构完整性,稳定性和免疫性进行了比较,与gB trimers进行了比较.
- 临床前研究包括对小鼠和非人类灵长类动物 (NHPs) 的免疫接种,随后是被动转移实验和对人性化小鼠的挑战研究.
主要成果:
- 与gB修剪机相比,gB-I53-50 NP的结构完整性和稳定性得到了改善.
- 纳米粒子疫苗在小鼠和NHP模型中都显示出增强的免疫性.
- 免疫接种和被动转移诱导了强大的,持久的抗体反应,在人性化的小鼠中提供了对致命的EBV挑战的保护.
结论:
- gB-I53-50 NP候选疫苗显示出预防EBV感染的巨大潜力.
- 这种纳米粒子平台为开发预防性EBV疫苗提供了一个有前途的战略.
相关概念视频
00:42Cross-reactivity
31.2K
Overview
31.2K
01:29Immune Response Against Viral Pathogens
798
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
798